Oral semaglutide trumps Jardiance, Januvia, Victoza in type II diabetes
Type II diabetes costs the NHS £8.8 billion a year.
Read More
Tag: Victoza
AZ bags two extensions in latest CHMP decisions
The Committee also recommended granting a marketing authorisation for La Jolla’s Giapreza, among other decisions.
Read More
Recent Ozempic, Victoza data ‘promising’ for diabetic kidney disease
Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk talks exclusively to PharmaTimes.
Read More
Novo Nordisk’s Victoza found to cut blood sugar in children
The ELLIPSE trial is the first Phase III trial completed in over a decade in children and adolescents with type II diabetes.
Read More
Novo Nordisk launches type II diabetes awareness campaign
Novo Nordisk UK is launching a campaign to raise awareness of the risk of heart attacks and strokes in people living with type II diabetes.
Read More
EU approves CV benefit claim for Novo’s Victoza
Novo Nordisk’s diabetes drug Victoza is now approved in Europe as the only GLP-1 analogue with a label including prevention of cardiovascular events.
Read More
Novo gets US backing for Victoza cardiovascular data
US regulatory advisors are backing the claim that Novo Nordisk’s Victoza reduces cardiovascular risk in patients with diabetes.
Read More
Trial shows heart benefits of Novo’s diabetes drug Victoza
New data on Novo Nordisk’s diabetes therapy Victoza show that the drug significantly cut the risk of major cardiovascular events and death in adults with type II diabetes.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
